Candida Isolation During COVID-19: Microbiological Findings of a Prospective Study in a Regional Hospital
View abstract on PubMed
Summary
This summary is machine-generated.The COVID-19 pandemic saw increased invasive candidiasis risk. Candida albicans and C. glabrata were common, with some C. glabrata strains resistant to fluconazole, necessitating susceptibility testing for effective antifungal treatment.
Area Of Science
- Medical Mycology
- Infectious Diseases
- Critical Care Medicine
Background
- The COVID-19 pandemic led to prolonged hospitalizations, increasing risk factors for invasive candidiasis.
- Understanding the spectrum of Candida species and their antifungal resistance is crucial in hospitalized patients.
Purpose Of The Study
- To identify Candida species isolated from patients with suspected COVID-19.
- To analyze antifungal susceptibility profiles and associated risk factors.
- To investigate the prevalence of co-infections and their clinical implications.
Main Methods
- Analysis of 42 clinical isolates from 33 patients with comorbidities using VITEK® MS Plus for identification.
- Antifungal susceptibility testing performed with VITEK® 2 Compact and AST-YS08 card.
Main Results
- Candida albicans and Candida glabrata were the most frequent isolates.
- Saprochaete capitata, an uncommon yeast, was also identified.
- 44% of Candida glabrata isolates showed fluconazole resistance but remained susceptible to caspofungin.
- Mechanical ventilation was a significant predisposing factor for co-infections.
Conclusions
- The study highlights an increased isolation of Candida species during the COVID-19 pandemic.
- Accurate etiological identification and susceptibility testing are vital for targeted antifungal therapy.
- Establishing clear criteria for Candida colonization versus infection is essential to optimize treatment and reduce hospital-associated risks.

